Michael R. Jirousek

8.9k citations

60 papers · 4.7k indexed · 2 hit papers · h-index 29

Geriatrics and Gerontology top 0.2%
- Sirtuins and Resveratrol in Medicine 8
Toxicology top 0.5%
- Bioactive Compounds and Antitumor Agents 8
Physiology top 1%
- Biochemical effects in animals 5
- Adipose Tissue and Metabolism 5
Ophthalmology top 1%
Molecular Biology top 2%
- Protein Tyrosine Phosphatases 15
- Protein Kinase Regulation and GTPase Signaling 11
- Metabolism, Diabetes, and Cancer 4
Immunology
- Galectins and Cancer Biology 11

Co-authors: Jacques Ermolieff Theodore Johnson Peter G. Goekjian James M. Trevillyan George L. King Jill C. Milne Peter J. Elliott J. Joshua Smith
Cited by: Geriatrics and Gerontology Toxicology Physiology
Partner nations: United States United Kingdom China

In The Last Decade

Michael R. Jirousek

59 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2002 Protein tyrosine phosphatase 1B inhibitors for diabetes
1997 Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor

Peers

Countries citing papers authored by Michael R. Jirousek

Since Specialization

Citations

This map shows the geographic impact of Michael R. Jirousek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Jirousek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Jirousek more than expected).

Fields of papers citing papers by Michael R. Jirousek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Jirousek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Jirousek. The network helps show where Michael R. Jirousek may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael R. Jirousek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael R. Jirousek Line = papers co-authored together Michael R. Jirousek links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice Michael Zimmer,Pradeep Bista,Ericka L. Benson,Diana Lee,Feng Liu,Dominic Picarella,Rick B. Vega,Chi B. Vu,Maisy Yeager,Min Ding,Guosheng Liang,Jay D. Horton,Robert Kleemann,Teake Kooistra,Martine C. Morrison,Peter Y. Wielinga,Jill C. Milne,Michael R. Jirousek,Andrew J. Nichols	2017	17
2	Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle David W. Hammers,Margaret M. Sleeper,Sean C. Forbes,Cora C. Coker,Michael R. Jirousek,Michael Zimmer,Glenn A. Walter,H. Lee Sweeney	2016	40
3	PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF CAT-2003, A NOVEL ACTIVATOR OF LIPOPROTEIN LIPASE, DEMONSTRATES REDUCTIONS IN POSTPRANDIAL TRIGLYCERIDES Joanne M. Donovan,Richard L. Dunbar,Lucasz Biernat,Douglas Logan,Michael J. Curtis,Maria Mancini,Michael R. Jirousek	2014	6
4	Discovery of Imidazo[1,2- b ]thiazole Derivatives as Novel SIRT1 Activators Chi B. Vu,Jean E. Bemis,Jeremy S. Disch,Pui Yee Ng,Joseph J. Nunes,Jill C. Milne,David P. Carney,Amy V. Lynch,J. Joshua Smith,Siva Lavu,Philip Lambert,David Gagné,Michael R. Jirousek,Simon Schenk,Jerrold M. Olefsky,Robert B. Perni	2009	101
5	Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo J. Joshua Smith,Renée Deehan Kenney,David Gagné,Brian P. Frushour,William Ladd,Heidi L. Galonek,Kristine Israelian,Jeffrey Song,Giedre Razvadauskaite,Amy V. Lynch,David P. Carney,Robin J. Johnson,Siva Lavu,André Iffland,Peter J. Elliott,Philip Lambert,Keith Elliston,Michael R. Jirousek,Jill C. Milne,Olivier Boss	2009	168
6	Discovery of benzothiazole derivatives as efficacious and enterocyte-specific MTP inhibitors Chi B. Vu,Jill C. Milne,David P. Carney,Jeffrey Song,Wendy Choy,Philip Lambert,David Gagné,Michael L. Hirsch,Angela Cote,Meghan F. Davis,Elden Lainez,Nekeya Meade,Karl Normington,Michael R. Jirousek,Robert B. Perni	2009	23
7	Crystal Structures of Human SIRT3 Displaying Substrate-induced Conformational Changes Lei Jin,Wentao Wei,Yaobin Jiang,Hao Peng,CAI JIAN-HUA,Mao Chen,Han Dai,Wendy Choy,Jean E. Bemis,Michael R. Jirousek,Jill C. Milne,Christoph Westphal,Robert B. Perni	2009	176
8	Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors Hongyu Zhao,Gang Liu,Zhili Xin,Michael D. Serby,Zhonghua Pei,Bruce G. Szczepankiewicz,Philip J. Hajduk,Cele Abad‐Zapatero,Charles W. Hutchins,Thomas Lübben,Stephen J. Ballaron,Deanna L. Haasch,Wiweka Kaszubska,Cristina M. Rondinone,James M. Trevillyan,Michael R. Jirousek	2004	74
9	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ Margaret M. Faul,James R. Gillig,Michael R. Jirousek,Lawrence M. Ballas,Theo Schotten,Astrid Kahl,Michael Möhr	2003	83
10	Identification of a monoacid-Based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B Zhili Xin,Gang Liu,Cele Abad‐Zapatero,Zhonghua Pei,Bruce G. Szczepankiewicz,Xiaofeng Li,Tianyuan Zhang,Charles W. Hutchins,Philip J. Hajduk,Stephen J. Ballaron,Michael A. Stashko,Thomas Lübben,James M. Trevillyan,Michael R. Jirousek	2003	52
11	PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat Jeffrey F. Waring,Rita Ciurlionis,Jill E. Clampit,Sherry J. Morgan,Rebecca J. Gum,Robert A. Jolly,Paul Kroeger,Leigh Frost,James M. Trevillyan,Bradley A. Zinker,Michael R. Jirousek,Roger G. Ulrich,Cristina M. Rondinone	2003	33
12	Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors Zhonghua Pei,Xiaofeng Li,Gang Liu,Cele Abad‐Zapatero,Tom Lubben,Tianyuan Zhang,Stephen J. Ballaron,Charles W. Hutchins,James M. Trevillyan,Michael R. Jirousek	2003	23
13	Protein tyrosine phosphatase 1B inhibitors for diabetesbreakdown → Theodore Johnson,Jacques Ermolieff,Michael R. Jirousek	2002	564
14	Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line Wiweka Kaszubska,Hugh D. Falls,Verlyn G. Schaefer,Deanna L. Haasch,Leigh Frost,Paul Hessler,Paul E. Kroeger,David W. White,Michael R. Jirousek,James M. Trevillyan	2002	150
15	Protein kinase C inhibitors as novel anticancer drugs Michael R. Jirousek,Peter G. Goekjian	2001	153
16	In Vitro Enzymatic Assays of Protein Tyrosine Phosphatase 1B Thomas Lübben,Jill E. Clampit,Michael A. Stashko,James M. Trevillyan,Michael R. Jirousek	2001	10
17	Protein Kinase C in the Treatment of Disease: Signal Transduction Pathways, Inhibitors, and Agents in Development Peter G. Goekjian,Michael R. Jirousek	1999	121
18	Effects of protein kinase C inhibitors on thromboxane production by thrombin-stimulated platelets Gennady P. Samokhin,Michael R. Jirousek,D. Kirk Ways,Ruth Ann Henriksen	1999	9
19	Synthesis of bisindolylmaleimides using a palladium catalyzed cross-coupling reaction David A. Neel,Michael R. Jirousek,John H. McDonald	1998	18
20	Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitorbreakdown → Lloyd Paul Aiello,Sven-Erik Bursell,Allen C. Clermont,Elia J. Duh,Hidehiro Ishii,Chikako Takagi,Fumi Mori,Thomas A. Ciulla,Kirk Ways,Michael R. Jirousek,Lois E. H. Smith,George L. King	1997	515

About Michael R. Jirousek

Michael R. Jirousek is a scholar working on Toxicology, Geriatrics and Gerontology and Immunology, having authored 60 papers that have together received 4.7k indexed citations. Recurring topics across this work include Protein Tyrosine Phosphatases (15 papers), Protein Kinase Regulation and GTPase Signaling (11 papers), Galectins and Cancer Biology (11 papers), Bioactive Compounds and Antitumor Agents (8 papers), Sirtuins and Resveratrol in Medicine (8 papers), Biochemical effects in animals (5 papers), Adipose Tissue and Metabolism (5 papers) and Metabolism, Diabetes, and Cancer (4 papers). The work is most often cited by research in Geriatrics and Gerontology (739 citations), Toxicology (340 citations) and Physiology (210 citations). Michael R. Jirousek has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Jacques Ermolieff, Theodore Johnson, Peter G. Goekjian, James M. Trevillyan, George L. King, Jill C. Milne, Peter J. Elliott, J. Joshua Smith, Cristina M. Rondinone and Zhonghua Pei.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact